PALBOciclib (Ibrance®)







Printed: 13/May/2020

* P L B - 0 0 0 0 0 - 0 4 - c N - B R *					
Name: Nationality: Gender/Age:			File Civi DOE	I ID:	Ht (cm): Wt (Kg): BSA (m²):
Indication(s): Metastatic breast cancer, HR +ve, HER2 -ve (in combination with either Fulvestrant or LEtrozole). Central line: □ Available □ NA Allergies: □ NKA □ Yes, specify;					
Standard Protocol:					
DRUG		DOSE		ADMINISTRATION	DAYS
PALBOciclib 125 mg PO		125 mg PO o	daily To be given with a meal approximately at the same D1 - 21 time each day, swallow whole, and don't crush, chew, or open capsule.		
To be repeated every 4 weeks until disease progression or intolerable toxicity.					
Special instructions: In case of missed dose or vomiting, don't take an additional dose and resume doseing with the next scheduled daily dose.					
Treatment Description:					
Cycle	Day	Date	PALBOciclib	Physician	Consultant
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
C#	D1 - 21				
Important Notes: Reported grade 3/4 toxicities: □ None □ Hematological □ Non-Hematological If yes; Did it indicate hospitalization? □ Yes □ No Did it indicate chemo-delay for ≥ 7 days? □ Yes □ No Did it indicate dose reduction? □ Yes □ No Did it indicate G-CSF support? □ Yes □ No					